Associate ProfessorT: 514-398-8137聽 | elias.georges [at] mcgill.ca (贰尘补颈濒听) |聽 Parasitology Building P-106 | |
Degrees
BSc, PhD (不良研究所)
Short Bio
Elias Georges trained as a biochemist and protein/peptide chemist. Following his Ph.D. at the Dept. of Biochemistry/不良研究所 working on the structure and function of intermediate filaments of the CNS (e.g., Neurofilaments), he spent six years as a Post-doc and research fellow at Princess Margaret Cancer Centre working on Multidrug resistance and P-glycoprotein (ABCB1) with Dr. Victor Ling. In 1991, he joined the Institute of Parasitology-不良研究所 as an Assistant Professor to work on drug resistance in Malaria, while continuing with his work on ABC-mediated drug resistance in cancer cells. In 1997, he was promoted to an Associate professor at the Institute of parasitology. In 1998, he co-founded Aurelium BioPharma Inc. (不良研究所 Spin-off biotechnology company focusing on the development of diagnostic tests and therapeutic antibodies for the treatment of breast and ovarian cancers). He is currently serving as the Canadian Pacific Chair in Biotechnology at 不良研究所 (2013 鈥� 2019). He is the Associate Editor-in Chief of International Journal of Biochemistry and Molecular Biology.聽From 2003 to 2009, he served as the Program Director for the Biotechnology Graduate Program at 不良研究所, and again holds the role of Director, Biotechnology Programs as of November 2021.
Awards and Recognitions
Young Investigator Award
CP Chair in Biotechnology
Research Interests
- Drug resistance mechanisms in malaria and聽the role of the聽Plasmodium falciparum聽Chloroquine Resistance Transporter (or PfCRT), and PfMDR1 and PfABCG as mediator of drug resistance to anti-malarial drugs
- Understanding the molecular mechanism of collateral sensitivity in drug resistant cancer cells to provide the first effective cancer treatment
- Cellular pathway mapping and protein interactions using peptide scanning approach to identify and study protein-protein interactions of the human ABC transporters鈥� Interactome.
Courses
Publications
Selected Publications
(2017) Apigenin-induced ABCC1-mediated efflux of glutathione from mature erythrocytes inhibits the proliferation of Plasmodium falciparum. Int J Antimicrob Agents 50: 673-677.
(2017) Sequences in Linker-1 domain of the multidrug resistance associated protein (MRP1 or ABCC1) bind to tubulin and their binding is modulated by phosphorylation. Biochem Biophys Res Commun 482: 1001-1006.
(2015) 3-Halo Chloroquine Derivatives Overcome Plasmodium falciparum Chloroquine Resistance Transporter-Mediated Drug Resistance in P. falciparum. Antimicrob Agents Chemother 59: 7891-3.
(2015) Characterization of native PfABCG protein in Plasmodium falciparum. Biochem Pharmacol 97: 137-46.
(2014) A 2-amino quinoline, 5-(3-(2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctan oic acid, interacts with PfMDR1 and inhibits its drug transport in Plasmodium falciparum. Mol Biochem Parasitol 195: 34-42.
(2012) Human ABCC1 interacts and colocalizes with ATP synthase alpha, revealed by interactive proteomics analysis. J Proteome Res 11: 1364-72.
(2011) Mutation of cysteine 21 inhibits nucleophosmin/B23 oligomerization and chaperone activity. Int J Biochem Mol Biol 2: 24-30.
(2011) RNAi-mediated knockdown of alpha-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics. Int J Biochem Mol Biol 2: 303-8.
(2009) P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. Arch Biochem Biophys 491: 53-60.
